相关实验视频
Updated: Jun 18, 2025

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.5K
重新定义斯坦丁剂量 胃外置术后:来自人口药理动力学-药理动力学链接方法的见解
Ana Carolina Conchon Costa1, Jose Ivan Marques Medeiros2, Wonho Kang1
1Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Journal of clinical pharmacology
|August 5, 2024
概括
鲁克斯-en-Y胃绕道 (RYGB) 显著减少了对simvastatin乳 (SV) 和其活性代谢物 (SVA) 的暴露40%. 后RYGB患者可能需要更高的simvastatin剂量或非他类药物,以获得类似的降胆固醇效果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 鲁克斯-en-Y胃绕道 (RYGB) 改变了胃肠道解剖学,可能会影响药物的药理动力学.
- 辛巴斯塔丁是一种用于胆固醇管理的常用药物.
- RYGB对simvastatin药理动力学和药理动力学的影响尚未得到充分研究.
研究的目的:
- 评估RYGB对simvastatin乳 (SV) 和simvastatin氧酸 (SVA) 药理学的影响.
- 建立一个人群的药理动力学-药理动力学 (PK/PD) 模型,以优化RYGB患者的simvastatin剂量.
- 为接受simvastatin治疗的RYGB患者提供剂量建议.
主要方法:
- 使用了一种种群体的药理动力学-药理动力学 (PK/PD) 建模方法.
- 分析了从RYGB患者和接受单次口服simvastatin剂量的对照患者的数据.
- 开发了一种包含肠肝循环的父代谢物模型,并与LDL胆固醇生产的药理动力学模型联系起来.
主要成果:
- 与对照组相比,RYGB患者的simvastatin乳 (SV) 和simvastatin氧酸 (SVA) 暴露减少了40%.
- 开发的PK/PD模型准确地描述了simvastatin的处置及其对LDL胆固醇的影响.
- 在RYGB患者中,模拟表明simvastatin标准剂量的疗效降低.
结论:
- RYGB手术显著减少了对simvastatin及其活性代谢物的暴露.
- RYGB患者可能需要增加simvastatin剂量 (例如,低强度为20 mg,中等强度为40-60 mg) 或与非他类药物联合治疗.
- 调整剂量策略对于实现治疗目标和预防RYGB后个体的不良事件至关重要.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
610
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
610
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
36
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
36
Nonlinear Pharmacokinetics: Overview
330
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
330
Analysis of Population Pharmacokinetic Data
244
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
244
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
147
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
147
Pharmacokinetics: Overview
6.1K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
6.1K

